<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26689589</article-id><article-id pub-id-type="pmc">4687145</article-id><article-id pub-id-type="publisher-id">160</article-id><article-id pub-id-type="doi">10.1186/s13195-015-0160-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>APLP1 as a cerebrospinal fluid biomarker for &#x003b3;-secretase modulator treatment</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sj&#x000f6;din</surname><given-names>Simon</given-names></name><address><phone>+46-31-343-00-41</phone><email>simon.sjodin@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Andersson</surname><given-names>Kerstin K. A.</given-names></name><address><email>kerstin.ka.andersson@vgregion.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mercken</surname><given-names>Marc</given-names></name><address><email>mmercken@its.jnj.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Zetterberg</surname><given-names>Henrik</given-names></name><address><email>henrik.zetterberg@clinchem.gu.se</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Borghys</surname><given-names>Herman</given-names></name><address><email>hborghys@its.jnj.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Blennow</surname><given-names>Kaj</given-names></name><address><email>kaj.blennow@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Portelius</surname><given-names>Erik</given-names></name><address><email>erik.portelius@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, M&#x000f6;lndal, S-431 80 Sweden </aff><aff id="Aff2"><label/>Janssen Research and Development, Beerse, Belgium </aff><aff id="Aff3"><label/>UCL Institute of Neurology, University College London, London, UK </aff></contrib-group><pub-date pub-type="epub"><day>22</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>7</volume><elocation-id>77</elocation-id><history><date date-type="received"><day>21</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>28</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Sj&#x000f6;din et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>Alzheimer&#x02019;s disease brains are characterized by extracellular plaques containing the aggregated amyloid &#x003b2;<sub>42</sub> (A&#x003b2;<sub>42</sub>) peptide and intraneuronal tangles containing hyperphosphorylated tau. A&#x003b2;<sub>42</sub> is produced by sequential processing of the amyloid precursor protein (APP) by &#x003b2;-secretase followed by &#x003b3;-secretase. Substantial efforts have been put into developing pharmaceuticals preventing the production or increasing the clearance of A&#x003b2;<sub>42</sub>. However, treatments inhibiting &#x003b3;-secretase have proven disappointing due to off-target effects. To circumvent these effects, &#x003b3;-secretase modulators (GSMs) have been developed, which rather than inhibiting &#x003b3;-secretase shift its preference into producing less aggregation-prone shorter A&#x003b2; peptides. Belonging to the same family of proteins as APP, amyloid-like protein 1 (APLP1) is also a substrate for &#x003b3;-secretase. Herein we investigated whether the GSM E2012 affects APLP1 processing in the central nervous system by measuring APLP1 peptide levels in cerebrospinal fluid (CSF) before and after E2012 treatment in dogs.</p></sec><sec><title>Methods</title><p>An in-house monoclonal APLP1 antibody, AP1, was produced and utilized for immunopurification of APLP1 from human and dog CSF in a hybrid immuno-affinity mass spectrometric method. Seven dogs received a single dose of 20 or 80&#x000a0;mg/kg of E2012 in a randomized cross-over design and CSF was collected prior to and 4, 8 and 24&#x000a0;hours after dosing.</p></sec><sec><title>Results</title><p>We have identified 14 CSF APLP1 peptides in humans and 12 CSF APLP1 peptides in dogs. Of these, seven were reproducibly detectable in dogs who received E2012. We found a dose-dependent relative increase of the CSF peptides APLP1&#x003b2;17, 1&#x003b2;18 and 1&#x003b2;28 accompanied with a decrease of 1&#x003b2;25 and 1&#x003b2;27 in response to E2012 treatment. All peptides reverted to baseline over the time of sample collection.</p></sec><sec><title>Conclusion</title><p>We show an in vivo effect of the GSM E2012 on the processing of APLP1 which is measurable in CSF. These data suggest that APLP1 peptides may be used as biomarkers to monitor drug effects of GSMs on &#x003b3;-secretase processing in clinical trials. However, this requires further investigation in larger cohorts, including studies in man.</p></sec></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsr&#x000e5;det (SE)</institution></institution-wrap></funding-source><award-id>14002</award-id><principal-award-recipient><name><surname>Zetterberg</surname><given-names>Henrik</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003792</institution-id><institution>Hj&#x000e4;rnfonden (SE)</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007464</institution-id><institution>Torsten Soderbergs Stiftelse (SE)</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Alzheimer&#x02019;s disease (AD) is a progressive neurodegenerative disorder and the most prevalent form of dementia [<xref ref-type="bibr" rid="CR1">1</xref>]. It is characterized by extracellular plaques, containing aggregated amyloid-&#x003b2; (A&#x003b2;) peptides [<xref ref-type="bibr" rid="CR2">2</xref>], and intraneuronal tangles consisting of hyperphosphorylated tau [<xref ref-type="bibr" rid="CR3">3</xref>]. In the amyloid cascade hypothesis, it is postulated that there is an imbalance in the production and/or clearance of A&#x003b2; which is believed to cause a series of events including microglial activation, oxidative stress, neuronal dysfunction, formation of tangles and inevitable neurodegeneration [<xref ref-type="bibr" rid="CR4">4</xref>]. For these reasons, targeting the production of the aggregation prone and potentially toxic 42 amino acid residue-long variant of A&#x003b2; (A&#x003b2;<sub>42</sub>) has been subject to extensive research with the aim of developing disease modifying compounds that inhibits or modulates the enzymes responsible for the formation of A&#x003b2; (see elaborating reviews elsewhere [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]).</p><p>The amyloid precursor protein (APP) is subjected to proteolytic processing by three secretases: &#x003b1;-secretase, &#x003b2;-secretase and &#x003b3;-secretase. The proteolytic activity of &#x003b1;-secretase is likely attributed to the protein disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) [<xref ref-type="bibr" rid="CR8">8</xref>]; &#x003b2;-secretase has been identified as &#x003b2;-site APP-cleaving enzyme (BACE) [<xref ref-type="bibr" rid="CR9">9</xref>]; whereas &#x003b3;-secretase is a multisubunit protein complex consisting of nicastrin (NCSTN), anterior pharynx-defective 1 (APH-1), presenilin enhancer 2 (PEN2) and the N- and C-terminal fragments of presenilin 1 or 2 (PS1 or PS2) [<xref ref-type="bibr" rid="CR10">10</xref>]. A&#x003b2;<sub>42</sub> is produced through the amyloidogenic pathway where APP is cleaved by &#x003b2;-secretase [<xref ref-type="bibr" rid="CR9">9</xref>] and subsequently by &#x003b3;-secretase [<xref ref-type="bibr" rid="CR11">11</xref>]. Alternatively A&#x003b2;<sub>42</sub> production is prevented in the non-amyloidogenic pathway where &#x003b1;-secretase rather than &#x003b2;-secretase cleaves APP within the A&#x003b2; sequence generating shorter A&#x003b2; peptides [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Secretases are an appealing target to alter the metabolism of A&#x003b2;. However, recent clinical trials where AD patients were treated with &#x003b3;-secretase inhibitors failed to reach their primary clinical endpoints; the cognitive decline was even worse in the treatment arm than in placebo [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. A diverse array of transmembrane proteins have been identified as &#x003b3;-secretase substrates [<xref ref-type="bibr" rid="CR15">15</xref>], including Notch [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], and the problems associated with &#x003b3;-secretase inhibitor treatment may be explained by the physiological functions of these substrates [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>To overcome the possible negative effects of inhibiting &#x003b3;-secretase, &#x003b3;-secretase modulators (GSMs) have been developed to shift the production from the amyloidogenic A&#x003b2;<sub>42</sub> to less aggregation-prone peptides (e.g<italic>.</italic>, A&#x003b2;<sub>38</sub>) without affecting the release of the intracellular domains of APP and other &#x003b3;-secretase substrates such as Notch1, cadherins, Erb4 and EphB2 [<xref ref-type="bibr" rid="CR18">18</xref>]. Thus, these compounds modulate the cleavage pattern of A&#x003b2; without inhibiting, for example, Notch signaling. The effect of GSMs on APP processing has previously been shown to be measurable in vivo in cerebrospinal fluid (CSF) from, for example, monkeys [<xref ref-type="bibr" rid="CR19">19</xref>] and guinea pigs [<xref ref-type="bibr" rid="CR20">20</xref>], where the level of A&#x003b2;<sub>42</sub> decreased and A&#x003b2;<sub>37</sub> or A&#x003b2;<sub>38</sub> increased [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In agreement with these studies, we recently showed that dogs treated with the GSM E2012 displayed a distinct shift in the CSF A&#x003b2; peptide pattern with decreased levels of A&#x003b2;<sub>42</sub> as well as A&#x003b2;<sub>39</sub> and A&#x003b2;<sub>40</sub> accompanied with increased levels of A&#x003b2;<sub>37</sub> [<xref ref-type="bibr" rid="CR21">21</xref>]. The effects of different GSMs on A&#x003b2; production have been summarized in a review by Crump et al. [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>Amyloid-like protein 1 (APLP1) and APP share, to a large extent, similar structural domains and are both suggested to be involved in neurite outgrowth, cell adhesion and neuronal migration [<xref ref-type="bibr" rid="CR23">23</xref>]. APLP1 and APP are also known to form heterodimers with possible implications in cell adhesion and synaptogenesis [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. APLP1 has been suggested to be processed by the same enzymatic activities as APP including &#x003b3;-secretase and &#x003b1;-secretase, generating a p3-like peptide called ALP-1 [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>], similar to the putative p3 fragment identified as a possible proteolytic product from APP [<xref ref-type="bibr" rid="CR27">27</xref>]. While it is established that &#x003b3;-secretase is responsible for the C-terminal processing of APLP1 [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>], the secretase cleaving at the N-terminus has been suggested to be either &#x003b1;- [<xref ref-type="bibr" rid="CR26">26</xref>] or &#x003b2;-secretase [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p>Recently, it was shown that APLP is processed into short A&#x003b2;-like peptides (APLP1&#x003b2;25, 1&#x003b2;27 and 1&#x003b2;28) [<xref ref-type="bibr" rid="CR28">28</xref>] and that the concentrations of CSF APLP1&#x003b2;25 and 1&#x003b2;27 were decreased while the concentration of CSF APLP1&#x003b2;28 was unchanged in four different PS1 mutation carriers [<xref ref-type="bibr" rid="CR32">32</xref>] leading to an increased APLP1&#x003b2;28 to total APLP1&#x003b2; ratio [<xref ref-type="bibr" rid="CR28">28</xref>]. In addition, cells treated with the A&#x003b2;<sub>42</sub> raising GSM S2474, or cells harboring certain PS1 mutations were also found to have an increased APLP1&#x003b2;28 to total APLP1&#x003b2; ratio and it was suggested that this ratio may reflect the A&#x003b2;<sub>42</sub> production in the brain [<xref ref-type="bibr" rid="CR28">28</xref>]. However, how the S2474 treatment or PS1 mutations affected the APLP1&#x003b2;28 concentrations were not reported. Whether APLP1 peptides can be used as CSF AD biomarkers reflecting A&#x003b2;<sub>42</sub> production needs to be investigated in large clinical studies, including early clinical stage of AD, AD dementia and control subjects, in which other CSF and imaging biomarkers are included.</p><p>In order to characterize APLP1 in CSF, we developed a monoclonal antibody directed against APLP1. We then used hybrid immuno-affinity-based enrichment of CSF APLP1 peptides from dogs followed by mass spectrometry (MS) analysis. In the present study we tested the hypothesis that peptides derived from APLP1 can be used as in vivo biomarkers reflecting treatment with the second generation GSM E2012.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Chemicals</title><p>The &#x003b3;-secretase modulator E2012 (cas no. 870843-42-8, (3E)-1-[(1<italic>S</italic>)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-2-piperidinone) was synthesized according to the described procedure [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="Sec4"><title>Experimental animals</title><p>Beagle dogs were given a single oral dose of 20 and 80&#x000a0;mg/kg E2012 with a dosing interval of at least 1&#x000a0;week. The animals were exposed in a randomized cross-over study as previously described [<xref ref-type="bibr" rid="CR21">21</xref>]. The animals (seven males, age 6&#x02013;8 years) received the compound with a liquid meal between 7 and 8&#x000a0;am and 1&#x000a0;ml CSF was collected prior to the meal and 4, 8 and 24&#x000a0;hours after dosing. The meal consisted of 120&#x000a0;ml concentrated liquid (Convalescence support, one satchel dissolved in 112.5&#x000a0;ml warm water; Crown Pet Foods Ltd., Castle Cary, UK) to which the compounds had been added directly before feeding. CSF was collected from awake animals from the lateral ventricle via a cannula. The CSF was collected into polypropylene tubes, immediately placed on dry ice and stored at &#x02212;80&#x000a0;&#x000b0;C until analysis. The method for implanting and collecting CSF via the cannula in dogs has been described elsewhere [<xref ref-type="bibr" rid="CR34">34</xref>]. In brief, a hole was drilled in the cranium of the dogs into which the cannula was screwed. The cannula was positioned at the following coordinates: 38&#x02013;40&#x000a0;mm rostral to the occipital protuberance and 8&#x000a0;mm lateral to the center of the sagittal crest. The study was conducted according to protocol 2009-252-SD MECHPHA, approved by the Ethical Committee on Laboratory Animal Testing (Ethische Commissie Dierproeven, Johnson &#x00026; Johnson Pharmaceutical Research and Development, Beerse, Belgium).</p></sec><sec id="Sec5"><title>Generation of anti-APLP1 antibody</title><p>A monoclonal antibody against APLP1, named AP1, was generated by immunization of 8-week-old Balb/c mice with the KLH-conjugated peptide APLP1 (amino acid 568&#x02013;579, [UniProtKB:P51693]; Caslo ApS, Lyngby, Denmark) in complete Freund&#x02019;s adjuvant (Sigma-Aldrich Co., St Louis, MO, USA). After three dosages (approximately 75&#x000a0;&#x003bc;g/mouse), the spleen was removed and B cells were fused with the myeloma cell line SP2/0 following standard procedure. Approximately 10&#x000a0;days after fusion, cell media were screened for APLP1 antibodies using APLP1 full length and neurogranin (Caslo ApS) as a negative control. Clones which reacted with the APLP1 protein were further grown, subcloned and subsequently frozen in liquid nitrogen. The isotype was determined using a commercially available kit (Pierce Rapid Isotyping Kit-Mouse; Thermo Fisher Scientific Inc., Waltham, MA, USA). Finally, antibodies were purified using a protein G column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden).</p></sec><sec id="Sec6"><title>Immuno-affinity mass spectrometry</title><p>CSF collected prior to dosing and 4, 8 and 24&#x000a0;hours after dosing with 20 or 80&#x000a0;mg/kg E2012 was analyzed by hybrid immuno-affinity MS as described previously with some modifications [<xref ref-type="bibr" rid="CR21">21</xref>]. In brief, 4&#x000a0;&#x003bc;g of the in-house developed mouse monoclonal anti-APLP1 antibody AP1 was incubated with 25&#x000a0;&#x003bc;l magnetic beads conjugated to sheep anti-mouse IgG (Dynabeads M280, Invitrogen, Thermo Fisher Scientific Inc.). Beads with the AP1 antibody complex were then washed in phosphate-buffered saline and added to 600&#x000a0;&#x003bc;l CSF containing 0.0025&#x000a0;% Tween, to a total volume of 625&#x000a0;&#x003bc;l. CSF with added beads was incubated over night at +8&#x000a0;&#x000b0;C on a rocking platform. Elution of APLP1 was performed in a five-step procedure using a KingFisher mL Magnetic Particle Processors system (Thermo Fisher Scientific Inc.). The eluate was dried and redissolved in 5&#x000a0;&#x003bc;l 0.1&#x000a0;% formic acid in 20&#x000a0;% acetonitrile. The sample in solution was mixed in a 2:1 ratio with a sample matrix containing 15&#x000a0;g/l alpha-cyano-4-hydroxycinnamic acid and 0.1&#x000a0;% trifluoroacetic acid in acetonitrile and spotted on an MTP 384 target plate polished steel TF (Bruker Daltonics GmbH, Bremen, Germany) with a seed layer containing 20&#x000a0;g/l alpha-cyano-4-hydroxycinnamic acid in 10&#x000a0;% methanol and 90&#x000a0;% acetone. The samples were analyzed as duplicates by matrix-assisted laser desorption ionization time-of-flight/time-of-flight (MALDI-TOF/TOF) using an UltrafleXtreme (Bruker Daltonics GmbH) mass spectrometer operating at positive reflector mode. The sample spectra acquired were processed using flexAnalysis v3.3 (Bruker Daltonics GmbH) by performing baseline subtraction, smoothening and internal calibration based on the theoretical monoisotopic masses of APLP1 fragments 1&#x003b2;17 (1615.79&#x02009;<italic>m/z</italic>), 1&#x003b2;18 (1728.88&#x02009;<italic>m/z</italic>), 1&#x003b2;22 (2143.11&#x02009;<italic>m/z</italic>), 1&#x003b2;25 (2328.19&#x02009;<italic>m/z</italic>), 1&#x003b2;27 (2472.24&#x02009;<italic>m/z</italic>) and 1&#x003b2;28 (2585.32&#x02009;<italic>m/z</italic>). Exported peak lists were subjected to processing by an in-house MATLAB (Mathworks Inc., Natick, Massachusetts, USA) program which, in short, relative to the monoisotopic peak, integrated the peak areas within the limits of &#x02212;2 to +5&#x02009;<italic>m/z</italic>. Following this, the integrated peak areas in each specific spectrum were normalized as the percentage of the total area of all peaks measured. Duplicate measurements were averaged and then a fold-change was calculated for samples acquired at 4, 8 and 24&#x000a0;hours against the sample collected prior to dosing as baseline.</p></sec><sec id="Sec7"><title>Tandem mass spectrometric identification of peptides</title><p>Employing collision-induced dissociation and the LIFT technology of the UltrafleXtreme, tandem MS (MS/MS) spectra of selected APLP1 peptides were acquired. These were processed and annotated in the BioTools software v3.2 (Bruker Daltonics GmbH) by employing an in-house Mascot Deamon server&#x000a0;(v2.3.2; Matrix Science Ltd. London, UK) search against an in-house designated APLP1 [UniProtKB:P51693] database. The parameters for searching the database were set to singly charged ions, variable methionine oxidation, a mass tolerance of 200&#x000a0;ppm, MS/MS tolerance of 0.5&#x000a0;Da and a MALDI-TOF/TOF instrumentation. MS and MS/MS spectra were also acquired from human CSF using the same sample preparation methodology as described above. CSF samples were supplied by clinical routine at the Clinical Neurochemistry Laboratory, The Sahlgrenska University Hospital, M&#x000f6;lndal, Sweden, in accordance with ethical approval from the regional ethics committee at the University of Gothenburg. The samples were de-identified by pooling.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>Statistical analysis was performed using GraphPad PRISM v6.04 (GraphPad Software, Inc., San Diego, USA) comparing the fold-change within each of the doses for the indicated peptides with Friedman test and employing Dunn&#x02019;s test for correction of multiple comparisons. Significant results were considered differences with a calculated <italic>p</italic>-value of &#x0003c;0.05.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Identification of APLP1 peptides in CSF</title><p>By combing the selectivity of the in-house mouse monoclonal antibody, AP1, and MS, we here for the first time show that several APLP1 derived peptides may be used as biomarkers for target engagement of the GSM E2012 in vivo.</p><p>The amino acid sequence for APLP1 for <italic>Canis familiaris</italic> and <italic>Homo sapiens</italic> has a 100&#x000a0;% homology [UniprotKB:J9JHP8 versus UniprotKB:P51693]. In total, 14 APLP1 peptides were identified in human CSF and 12 in dog CSF of which nine were confirmed by MS/MS (see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref> for all identified peptides). All confirmed peptides started with the aspartic acid found at amino acid 568 of APLP1 [UniprotKB:P51693] and included peptides ranging between APLP1&#x003b2;13 up to APLP1&#x003b2;28. An additional peak that had the mass of the peptide plus 16&#x000a0;Da, corresponding to oxidation of methionine at position 21, was also observed for several of the APLP peptides (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Fragment ion mass spectra used for the identification of APLP1&#x003b2;17 and APLP1&#x003b2;28 are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a and b</xref>, respectively.<fig id="Fig1"><label>Fig. 1</label><caption><p>Full mass spectrum of APLP1 immunoprecipitated from cerebrospinal fluid. APLP1 was immunoprecipitated from <bold>a</bold> dog or <bold>b</bold> human cerebrospinal fluid and subjected to MALDI-TOF/TOF in which a full mass spectrum was recorded. The peaks corresponding to the APLP1 peptides that have been identified by their corresponding theoretical masses or tandem mass spectrometry are annotated in the spectrum. The insert shows a magnification of the peaks detected between 1800 and 2250&#x02009;<italic>m/z</italic>. Additional peaks of +16&#x02009;<italic>m/z</italic> following APLP1&#x003b2;21 to 1&#x003b2;28 corresponds to oxidation of methionine at position 21. <italic>APLP1</italic> Amyloid-like protein 1</p></caption><graphic xlink:href="13195_2015_160_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>APLP1 precursor ion identification in full mass spectrum</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Sequence</th><th>Theoretical mass (Da)</th><th>Observed mass (Da) dogs</th><th>ppm dogs</th><th>Observed mass (Da) human</th><th>ppm human</th><th>Annotation</th></tr></thead><tbody><tr><td>DELAPAGTGVSRE</td><td char="." align="char">1300.63</td><td>1300.60</td><td>&#x02212;172</td><td char="." align="char">1300.63</td><td>39</td><td>APLP1&#x003b2;13</td></tr><tr><td>DELAPAGTGVSREA</td><td char="." align="char">1371.66</td><td>1371.65</td><td>&#x02212;114</td><td char="." align="char">1371.67</td><td>20</td><td>APLP1&#x003b2;14</td></tr><tr><td>DELAPAGTGVSREAVSG</td><td char="." align="char">1614.78</td><td>1614.78</td><td>&#x02212;8.5</td><td char="." align="char">1614.78</td><td>&#x02212;0.058</td><td>APLP1&#x003b2;17</td></tr><tr><td>DELAPAGTGVSREAVSGL</td><td char="." align="char">1727.87</td><td>1727.87</td><td>13</td><td char="." align="char">1727.87</td><td>0.12</td><td>APLP1&#x003b2;18</td></tr><tr><td>DELAPAGTGVSREAVSGLL</td><td char="." align="char">1840.95</td><td>1840.96</td><td>12</td><td char="." align="char">1840.95</td><td>&#x02212;8.2</td><td>APLP1&#x003b2;19</td></tr><tr><td>DELAPAGTGVSREAVSGLLI</td><td char="." align="char">1954.04</td><td>1954.04</td><td>8.5</td><td char="." align="char">1954.04</td><td>&#x02212;8.5</td><td>APLP1&#x003b2;20</td></tr><tr><td>DELAPAGTGVSREAVSGLLIM</td><td char="." align="char">2085.08</td><td>2085.08</td><td>&#x02212;2.4</td><td char="." align="char">2085.08</td><td>1.1</td><td>APLP1&#x003b2;21</td></tr><tr><td>DELAPAGTGVSREAVSGLLIMG</td><td char="." align="char">2142.10</td><td>2142.10</td><td>&#x02212;7.6</td><td char="." align="char">2142.10</td><td>&#x02212;0.46</td><td>APLP1&#x003b2;22</td></tr><tr><td>DELAPAGTGVSREAVSGLLIMGA</td><td char="." align="char">2213.14</td><td>&#x02013;</td><td>&#x02013;</td><td char="." align="char">2213.13</td><td>&#x02212;13</td><td>APLP1&#x003b2;23</td></tr><tr><td>DELAPAGTGVSREAVSGLLIMGAG</td><td char="." align="char">2270.16</td><td>&#x02013;</td><td>&#x02013;</td><td char="." align="char">2270.16</td><td>8.5</td><td>APLP1&#x003b2;24</td></tr><tr><td>DELAPAGTGVSREAVSGLLIMGAGG</td><td char="." align="char">2327.18</td><td>2327.18</td><td>3.3</td><td char="." align="char">2327.18</td><td>1.0</td><td>APLP1&#x003b2;25</td></tr><tr><td>DELAPAGTGVSREAVSGLLIMGAGGG</td><td char="." align="char">2384.20</td><td>2384.19</td><td>&#x02212;33</td><td char="." align="char">2384.19</td><td>&#x02212;65</td><td>APLP1&#x003b2;26</td></tr><tr><td>DELAPAGTGVSREAVSGLLIMGAGGGS</td><td char="." align="char">2471.23</td><td>2471.23</td><td>&#x02212;0.53</td><td char="." align="char">2471.23</td><td>&#x02212;0.91</td><td>APLP1&#x003b2;27</td></tr><tr><td>DELAPAGTGVSREAVSGLLIMGAGGGSL</td><td char="." align="char">2584.32</td><td>2584.32</td><td>0.72</td><td char="." align="char">2584.32</td><td>0.31</td><td>APLP1&#x003b2;28</td></tr></tbody></table><table-wrap-foot><p>Full mass spectra of amyloid-like protein 1 (APLP1) immunoprecipitated from dog and human cerebrospinal fluid were acquired by MALDI-TOF/TOF. The Table shows the amino acid sequences, the observed masses in Da in dogs and human and their deviation from the theoretical peptide mass in ppm for the peptides identified</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Tandem mass spectrometric identification of APLP1 peptides</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Peptide</th><th>Observed <italic>m/z</italic>
</th><th>ppm</th><th>Ion score</th><th>Expect</th><th>a/b/y ions</th></tr></thead><tbody><tr><td>APLP1&#x003b2;14</td><td char="." align="char">1372.71</td><td>30.4</td><td>48</td><td char="." align="char">1.6x10<sup>-5</sup>
</td><td>&#x02013;/4/6</td></tr><tr><td>APLP1&#x003b2;17</td><td char="." align="char">1615.83</td><td>23.7</td><td>79</td><td char="." align="char">1.3x10<sup>-8</sup>
</td><td>4/6/11</td></tr><tr><td>APLP1&#x003b2;18</td><td char="." align="char">1728.91</td><td>21.9</td><td>65</td><td char="." align="char">3.0x10<sup>-7</sup>
</td><td>&#x02013;/8/10</td></tr><tr><td>APLP1&#x003b2;19</td><td char="." align="char">1842.06</td><td>56.7</td><td>18</td><td char="." align="char">1.7x10<sup>-2</sup>
</td><td>&#x02013;/5/4</td></tr><tr><td>APLP1&#x003b2;21</td><td char="." align="char">2086.19</td><td>48.1</td><td>24</td><td char="." align="char">3.9x10<sup>-3</sup>
</td><td>&#x02013;/6/&#x02013;</td></tr><tr><td>APLP1&#x003b2;23</td><td char="." align="char">2214.14</td><td>&#x02212;2.91</td><td>15</td><td char="." align="char">3.3x10<sup>-2</sup>
</td><td>&#x02013;/4/&#x02013;</td></tr><tr><td>APLP1&#x003b2;25</td><td char="." align="char">2328.51</td><td>138</td><td>79</td><td char="." align="char">1.3x10<sup>-8</sup>
</td><td>7/6/11</td></tr><tr><td>APLP1&#x003b2;27</td><td char="." align="char">2472.31</td><td>27.8</td><td>100</td><td char="." align="char">9.4x10<sup>-11</sup>
</td><td>9/5/9</td></tr><tr><td>APLP1&#x003b2;28</td><td char="." align="char">2585.40</td><td>28.3</td><td>93</td><td char="." align="char">5.3x10<sup>-10</sup>
</td><td>9/11/10</td></tr></tbody></table><table-wrap-foot><p>The Table shows the peptides that were identified by tandem mass spectrometry. The acquired fragment mass spectra were used for searching an in-house Mascot Deamon server containing a designated amyloid-like protein 1 (APLP1) database. Also shown are the observed masses and the deviation from the theoretical masses in ppm, as well as identification statistics given as the Mascot Ion Score and Expect value. The number of identified a, b and y ions are also indicated</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Fragment ion mass spectra of APLP1 peptides. Fragment mass spectra generated by tandem mass spectrometry of the peptides <bold>a</bold> APLP1&#x003b2;17 and <bold>b</bold> APLP1&#x003b2;28 immunoprecipitated from human cerebrospinal fluid. Shown are the fragment ions annotated as a, b and y ions. The fragment spectra were used for identification and annotation by searching an in-house designated APLP1 database using a Mascot Daemon server</p></caption><graphic xlink:href="13195_2015_160_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec11"><title>Modulation of APLP1 processing by E2012 in dogs</title><p>In total, seven APLP1 peptides were reproducibly detected in all dog CSF samples (APLP1&#x003b2;17, 1&#x003b2;18, 1&#x003b2;21, 1&#x003b2;22, 1&#x003b2;25, 1&#x003b2;27 and 1&#x003b2;28) and their response to treatment with E2012 was further investigated. See Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> for representative mass spectra from a dog treated with 80&#x000a0;mg/kg of the GSM E2012.<fig id="Fig3"><label>Fig. 3</label><caption><p>Full mass spectrum of 80&#x000a0;mg/kg &#x003b3;-secretase modulation effect in dogs. Full mass spectra of APLP1 were acquired by hybrid immuno-affinity MALDI-TOF/TOF mass spectrometry. The spectra show the relative changes of the APLP1 peptides in cerebrospinal fluid collected from a dog <bold>a</bold> prior to dosing with 80&#x000a0;mg/kg of the &#x003b3;-secretase modulator E2012 and subsequently <bold>b</bold> 4, <bold>c</bold> 8 and <bold>d</bold> 24&#x000a0;hours after dosing. <italic>APLP1</italic> Amyloid-like protein 1</p></caption><graphic xlink:href="13195_2015_160_Fig3_HTML" id="MO3"/></fig></p><p>Four hours after administration of the GSM E2012 (80&#x000a0;mg/kg), we found higher levels of APLP1&#x003b2;17 (<italic>p</italic>&#x02009;=&#x02009;0.027) and APLP1&#x003b2;18 (<italic>p</italic>&#x02009;=&#x02009;0.016) compared to 8&#x000a0;hours post-treatment. The increases reverted to baseline levels at 8&#x000a0;hours post-treatment and remained at baseline levels 24&#x000a0;hours post-treatment (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a and b</xref>). No significant differences were observed for the two peptides after the 20&#x000a0;mg/kg dose (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a and b</xref>). After administration of 80&#x000a0;mg/kg, the levels of APLP1&#x003b2;25 were significantly decreased both at 4&#x000a0;hours (<italic>p</italic>&#x02009;=&#x02009;0.0032) and 8&#x000a0;hours (<italic>p</italic>&#x02009;=&#x02009;0.0032) post-treatment (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4e</xref>). The 20&#x000a0;mg/kg dose showed a similar trend without reaching statistical significance (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4e</xref>). APLP1&#x003b2;28 showed a dose-dependent increase at 8&#x000a0;hours post-treatment which was significant for 80&#x000a0;mg/kg (<italic>p</italic>&#x02009;=&#x02009;0.0032) but not 20&#x000a0;mg/kg (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4g</xref>). However, the increase at 8&#x000a0;hours was significant relative to 24&#x000a0;hours post-treatment for both doses (<italic>p</italic>&#x02009;=&#x02009;0.0032 and <italic>p</italic>&#x02009;=&#x02009;0.047 for 80&#x000a0;mg/kg and 20&#x000a0;mg/kg, respectively; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4g</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>Modulation of &#x003b3;-secretase processing of APLP1 in dogs. APLP1 was immunoprecipitated from cerebrospinal fluid collected from dogs prior to and 4, 8 and 24&#x000a0;hours after receiving 20 and 80&#x000a0;mg/kg of the &#x003b3;-secretase modulator E2012. Using MALDI-TOF/TOF, full mass spectra were recorded in which the intensity of the peak corresponding to a peptide was normalized against the intensity of all the peaks measured in the spectrum. Shown is the percent deviation from the sample collected prior to dosing (baseline) for the peptides <bold>a</bold> APLP1&#x003b2;17, <bold>b</bold> APLP1&#x003b2;18, <bold>c</bold> APLP1&#x003b2;21, <bold>d</bold> APLP1&#x003b2;22, <bold>e</bold> APLP1&#x003b2;25, <bold>f</bold> APLP1&#x003b2;27 and <bold>g</bold> APLP1&#x003b2;28. The measurements are shown as the mean (n&#x02009;=&#x02009;7) with 95&#x000a0;% confidence interval. Significant dose effects between time intervals were determined using Friedman test combined with Dunn&#x02019;s test for multiple comparisons and are indicated as *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 and **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01. <italic>APLP1</italic> Amyloid-like protein 1</p></caption><graphic xlink:href="13195_2015_160_Fig4_HTML" id="MO4"/></fig></p><p>APLP1&#x003b2;21 and APLP1&#x003b2;22 did not show any significant deviations from baseline for either of the two doses (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c and d</xref>). The level of APLP1&#x003b2;27 showed a trend towards decreased levels in a dose-dependent manner in response to treatment but it did not reach statistical significance for either of the doses (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4f</xref>).</p></sec></sec><sec id="Sec12" sec-type="discussion"><title>Discussion</title><p>In the present study, we show that APLP1 in CSF is present as a variety of short peptides. For the first time we also demonstrate that the levels of several CSF APLP1 peptides are markedly affected in response to treatment with the GSM E2012 suggesting that APLP1-derived peptides may be used as biomarkers to prove target engagement for this type of treatments. To our knowledge there are no studies of the effect of &#x003b3;-secretase modulators on APLP1 processing in vivo to date.</p><p>Previously, using an explorative proteomics approach, we identified eight endogenous APLP1 peptides in human CSF including APLP1&#x003b2;17, 1&#x003b2;18, 1&#x003b2;25 and 1&#x003b2;27 [<xref ref-type="bibr" rid="CR35">35</xref>]. By employing the targeted approach described herein we have identified and confirmed the presence of the previously identified peptides in CSF [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR35">35</xref>] and have now extended the list of identified endogenous APLP1 peptides. A previous report showed an increase of APLP1&#x003b2;28 relative to the total amount of APLP1 peptides in CSF from AD subjects [<xref ref-type="bibr" rid="CR28">28</xref>] while we recently showed that the levels of APLP1&#x003b2;25, 1&#x003b2;27 and 1&#x003b2;28 in CSF from Down&#x02019;s syndrome patients are decreased as compared to healthy controls [<xref ref-type="bibr" rid="CR36">36</xref>]. However, whether CSF APLP1&#x003b2;28 can be used as an AD or Down&#x02019;s syndrome biomarker needs to be investigated in large clinical studies.</p><p>Of the 12 identified APLP1 peptides in dog CSF, we show that several are affected in response to treatment with the GSM E2012 and that some peptides are affected in a dose-dependent manner as the effect was more pronounced with the higher dose (80&#x000a0;mg/kg). We found increased relative levels of APLP1&#x003b2;17, 1&#x003b2;18 and 1&#x003b2;28 in response to treatment accompanied by decreased relative levels of APLP1&#x003b2;25 and 1&#x003b2;27. The changes in the levels for all of the peptides seem to revert towards baseline levels over time. For APLP1&#x003b2;21 and 1&#x003b2;22 we found no significant difference. These findings suggest that the modulation of the APLP1 processing affects the production over the range of peptides present, not only a single peptide or exclusively shorter or longer peptides. Furthermore, the transmembrane region of APLP1 ranges from position 581&#x02013;603. Thus all identified APLP1 peptides, except APLP1&#x003b2;13, are located within this region and are accessible for &#x003b3;-secretase processing.</p><p>Previously we have shown that the CSF levels of A&#x003b2;<sub>37</sub> increases and A&#x003b2;<sub>42</sub> decreases in dogs treated with the GSM E2012 [<xref ref-type="bibr" rid="CR21">21</xref>]. Here we show in the very same material that the levels of several APLP1 peptides are affected in response to E2012 treatment. Thus investigating the level of APLP1 peptides in GSM treatment trials may be highly informative and possibly increase our understanding of the mechanistics and dynamics of APLP processing in the disease.</p><p>One limitation with the current study is that the epitope of the APLP1 antibody used (AP1) has not been determined. However MS analysis, including MS/MS, confirms that the peptides studied in the present study indeed are APLP1 derived. It should also be noted that the ratio between the different endogenous APLP1 peptides detected cannot be interpreted as a direct reflection of their absolute abundance in the CSF. This is because the ionization efficiency might be different for the different peptides. Phase I trials in man are needed to further study the potential of CSF APLP1 peptides to verify target engagement of GSM drug candidates as well as long-term clinical trials to examine if these biomarkers also may predict a beneficial clinical treatment effect.</p><p>With GSMs, one of the benefits is to avoid the potential inhibition of processing of non-intended substrates such as Notch [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>] which has been one of the main concerns when using &#x003b3;-secretase inhibitors. However, GSMs have also shown an effect on Notch processing but in respect to cleavage site preference and not inhibition [<xref ref-type="bibr" rid="CR37">37</xref>]. How GSMs affect the processing of the substrates is to a large extent unclear. It is likely dependent on the particular modulator used and the target with which it interacts [<xref ref-type="bibr" rid="CR22">22</xref>]. First generation GSMs have been hypothesized to interact with the substrate, the secretase, or both [<xref ref-type="bibr" rid="CR22">22</xref>], and it has been further speculated that, in the instance of modulators targeting the APP and A&#x003b2; sequences, this might affect the processing by adjusting the position of the amino acid sequence in relation to the membrane [<xref ref-type="bibr" rid="CR38">38</xref>]. Second-generation GSMs, to which E2012 belongs, have been shown rather to interact with the subunits of &#x003b3;-secretase [<xref ref-type="bibr" rid="CR22">22</xref>]. Specifically, E2012 has been indicated to bind to the N-terminal fragment of PS1 in a competitive manner [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p></sec><sec id="Sec13" sec-type="conclusion"><title>Conclusions</title><p>We have identified a number of APLP1 peptides in human and dog CSF. Furthermore we have shown that &#x003b3;-secretase modulation, using the GSM E2012, affects APLP1 proteolytic processing in vivo and that this is reflected in the relative levels of a number of APLP1 peptides. The soluble nature of the APLP1 peptides [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] and the fact that APLP1 is a &#x003b3;-secretase substrate, as indicated herein and shown elsewhere [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>], suggests that secreted APLP1 fragments may be informative when investigating &#x003b3;-secretase cleavage products in AD. Our findings show that APLP1 peptides can be used as in vivo biomarkers for E2012 treatment, which may be translated to other second-generation GSMs.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>A&#x003b2;</term><def><p>Amyloid &#x003b2;</p></def></def-item><def-item><term>AD</term><def><p>Alzheimer&#x02019;s disease</p></def></def-item><def-item><term>APLP1</term><def><p>Amyloid-like protein 1</p></def></def-item><def-item><term>APP</term><def><p>Amyloid precursor protein</p></def></def-item><def-item><term>CSF</term><def><p>Cerebrospinal fluid</p></def></def-item><def-item><term>GSM</term><def><p>&#x003b3;-Secretase modulator</p></def></def-item><def-item><term>MALDI-TOF/TOF</term><def><p>Matrix-assisted laser desorption ionization time-of-flight/time-of-flight</p></def></def-item><def-item><term>MS</term><def><p>Mass spectrometry</p></def></def-item><def-item><term>MS/MS</term><def><p>Tandem mass spectrometry</p></def></def-item><def-item><term>PS</term><def><p>Presenilin</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>HB and MM are employed by Janssen. SS, KKAA, HZ, KB and EP declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>SS performed the hybrid immuno-affinity mass spectrometry experiments, statistical analyses and drafted the manuscript. HB designed the study, facilitated the animal treatment regime and CSF collection and revised the draft for important intellectual content. KKAA produced the monoclonal antibody and revised the draft for important intellectual content. MM designed the study and revised the draft for important intellectual content. HZ designed the study and revised the draft for important intellectual content. KB designed the study, designed the production of anti-APLP antibodies and revised the draft for important intellectual content. EP designed the study and drafted the manuscript. All authors interpreted the data. All authors agree with the presented findings and read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was supported by grants from the Research Council, Sweden (grant #14002), Hj&#x000e4;rnfonden, and the Torsten S&#x000f6;derberg Foundation at the Royal Academy of Sciences.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Stern</surname><given-names>Y</given-names></name></person-group><article-title>Epidemiology of Alzheimer disease</article-title><source>Cold Spring Harb Perspect Med</source><year>2012</year><volume>2</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1101/cshperspect.a006239</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Simms</surname><given-names>G</given-names></name><name><surname>Weinman</surname><given-names>NA</given-names></name><name><surname>Multhaup</surname><given-names>G</given-names></name><name><surname>McDonald</surname><given-names>BL</given-names></name><name><surname>Beyreuther</surname><given-names>K</given-names></name></person-group><article-title>Amyloid plaque core protein in Alzheimer disease and Down syndrome</article-title><source>Proc Natl Acad Sci U S A</source><year>1985</year><volume>82</volume><fpage>4245</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.82.12.4245</pub-id><pub-id pub-id-type="pmid">3159021</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundke-Iqbal</surname><given-names>I</given-names></name><name><surname>Iqbal</surname><given-names>K</given-names></name><name><surname>Tung</surname><given-names>YC</given-names></name><name><surname>Quinlan</surname><given-names>M</given-names></name><name><surname>Wisniewski</surname><given-names>HM</given-names></name><name><surname>Binder</surname><given-names>LI</given-names></name></person-group><article-title>Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology</article-title><source>Proc Natl Acad Sci U S A</source><year>1986</year><volume>83</volume><fpage>4913</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.83.13.4913</pub-id><pub-id pub-id-type="pmid">3088567</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>Higgins</surname><given-names>GA</given-names></name></person-group><article-title>Alzheimer&#x02019;s disease: the amyloid cascade hypothesis</article-title><source>Science</source><year>1992</year><volume>256</volume><fpage>184</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1126/science.1566067</pub-id><pub-id pub-id-type="pmid">1566067</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Strooper</surname><given-names>B</given-names></name></person-group><article-title>Lessons from a failed gamma-secretase Alzheimer trial</article-title><source>Cell</source><year>2014</year><volume>159</volume><fpage>721</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.10.016</pub-id><pub-id pub-id-type="pmid">25417150</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer&#x02019;s disease: clinical trials and drug development. Lancet Neurol. 2010;9:702&#x02013;16. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1474-4422(10)70119-8">http://dx.doi.org/10.1016/S1474-4422(10)70119-8</ext-link>&#x000a0;(accessed 2015-11-09).</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citron</surname><given-names>M</given-names></name></person-group><article-title>Alzheimer&#x02019;s disease: strategies for disease modification</article-title><source>Nat Rev Drug Discov</source><year>2010</year><volume>9</volume><fpage>387</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/nrd2896</pub-id><pub-id pub-id-type="pmid">20431570</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>PH</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Dislich</surname><given-names>B</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Zeitschel</surname><given-names>U</given-names></name><name><surname>Ellwart</surname><given-names>JW</given-names></name><etal/></person-group><article-title>ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons</article-title><source>EMBO J</source><year>2010</year><volume>29</volume><fpage>3020</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/emboj.2010.167</pub-id><pub-id pub-id-type="pmid">20676056</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassar</surname><given-names>R</given-names></name><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Babu-Khan</surname><given-names>S</given-names></name><name><surname>Kahn</surname><given-names>S</given-names></name><name><surname>Mendiaz</surname><given-names>EA</given-names></name><name><surname>Denis</surname><given-names>P</given-names></name><etal/></person-group><article-title>Beta-secretase cleavage of Alzheimer&#x02019;s amyloid precursor protein by the transmembrane aspartic protease BACE</article-title><source>Science</source><year>1999</year><volume>286</volume><fpage>735</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1126/science.286.5440.735</pub-id><pub-id pub-id-type="pmid">10531052</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimberly</surname><given-names>WT</given-names></name><name><surname>LaVoie</surname><given-names>MJ</given-names></name><name><surname>Ostaszewski</surname><given-names>BL</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><name><surname>Wolfe</surname><given-names>MS</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>6382</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1073/pnas.1037392100</pub-id><pub-id pub-id-type="pmid">12740439</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Strooper</surname><given-names>B</given-names></name><name><surname>Saftig</surname><given-names>P</given-names></name><name><surname>Craessaerts</surname><given-names>K</given-names></name><name><surname>Vanderstichele</surname><given-names>H</given-names></name><name><surname>Guhde</surname><given-names>G</given-names></name><name><surname>Annaert</surname><given-names>W</given-names></name><etal/></person-group><article-title>Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein</article-title><source>Nature</source><year>1998</year><volume>391</volume><fpage>387</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/34910</pub-id><pub-id pub-id-type="pmid">9450754</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esch</surname><given-names>FS</given-names></name><name><surname>Keim</surname><given-names>PS</given-names></name><name><surname>Beattie</surname><given-names>EC</given-names></name><name><surname>Blacher</surname><given-names>RW</given-names></name><name><surname>Culwell</surname><given-names>AR</given-names></name><name><surname>Oltersdorf</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cleavage of amyloid beta peptide during constitutive processing of its precursor</article-title><source>Science</source><year>1990</year><volume>248</volume><fpage>1122</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1126/science.2111583</pub-id><pub-id pub-id-type="pmid">2111583</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doody</surname><given-names>RS</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Joffe</surname><given-names>S</given-names></name><etal/></person-group><article-title>A phase 3 trial of semagacestat for treatment of Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>341</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1210951</pub-id><pub-id pub-id-type="pmid">23883379</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coric</surname><given-names>V</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Brody</surname><given-names>M</given-names></name><name><surname>Richter</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><fpage>1430</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2012.2194</pub-id><pub-id pub-id-type="pmid">22892585</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JV</given-names></name><name><surname>Twomey</surname><given-names>C</given-names></name><name><surname>Wujek</surname><given-names>P</given-names></name></person-group><article-title>Presenilin-dependent regulated intramembrane proteolysis and &#x003b3;-secretase activity</article-title><source>Cell Mol Life Sci</source><year>2009</year><volume>66</volume><fpage>1534</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1007/s00018-009-8435-9</pub-id><pub-id pub-id-type="pmid">19189053</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Strooper</surname><given-names>B</given-names></name><name><surname>Annaert</surname><given-names>W</given-names></name><name><surname>Cupers</surname><given-names>P</given-names></name><name><surname>Saftig</surname><given-names>P</given-names></name><name><surname>Craessaerts</surname><given-names>K</given-names></name><name><surname>Mumm</surname><given-names>JS</given-names></name><etal/></person-group><article-title>A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain</article-title><source>Nature</source><year>1999</year><volume>398</volume><fpage>518</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/19083</pub-id><pub-id pub-id-type="pmid">10206645</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Struhl</surname><given-names>G</given-names></name><name><surname>Greenwald</surname><given-names>I</given-names></name></person-group><article-title>Presenilin is required for activity and nuclear access of Notch in Drosophila</article-title><source>Nature</source><year>1999</year><volume>398</volume><fpage>522</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/19091</pub-id><pub-id pub-id-type="pmid">10206646</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barthet</surname><given-names>G</given-names></name><name><surname>Georgakopoulos</surname><given-names>A</given-names></name><name><surname>Robakis</surname><given-names>NK</given-names></name></person-group><article-title>Cellular mechanisms of gamma-secretase substrate selection, processing and toxicity</article-title><source>Prog Neurobiol</source><year>2012</year><volume>98</volume><fpage>166</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2012.05.006</pub-id><pub-id pub-id-type="pmid">22622135</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>IF</given-names></name><name><surname>Golde</surname><given-names>TE</given-names></name><name><surname>Galasko</surname><given-names>DR</given-names></name><name><surname>Koo</surname><given-names>EH</given-names></name></person-group><article-title>Modulation of Abeta42 in vivo by gamma-secretase modulator in primates and humans</article-title><source>Alzheimers Res Ther</source><year>2015</year><volume>7</volume><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/s13195-015-0137-y</pub-id><pub-id pub-id-type="pmid">26244059</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Appelkvist</surname><given-names>P</given-names></name><name><surname>Str&#x000f6;mberg</surname><given-names>K</given-names></name><name><surname>H&#x000f6;glund</surname><given-names>K</given-names></name></person-group><article-title>Characterization of the effect of a novel &#x003b3;-secretase modulator on A&#x003b2;: a clinically translatable model</article-title><source>Curr Pharm Des</source><year>2014</year><volume>20</volume><fpage>2484</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.2174/13816128113199990499</pub-id><pub-id pub-id-type="pmid">23859556</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Van Broeck</surname><given-names>B</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Gustavsson</surname><given-names>MK</given-names></name><name><surname>Mercken</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><etal/></person-group><article-title>Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs</article-title><source>J Alzheimers Dis</source><year>2010</year><volume>21</volume><fpage>1005</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">20634579</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crump</surname><given-names>CJ</given-names></name><name><surname>Johnson</surname><given-names>DS</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name></person-group><article-title>Development and mechanism of gamma-secretase modulators for Alzheimer&#x02019;s disease</article-title><source>Biochemistry</source><year>2013</year><volume>52</volume><fpage>3197</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1021/bi400377p</pub-id><pub-id pub-id-type="pmid">23614767</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname><given-names>KT</given-names></name><name><surname>Iverfeldt</surname><given-names>K</given-names></name></person-group><article-title>Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors</article-title><source>Cell Mol Life Sci</source><year>2009</year><volume>66</volume><fpage>2299</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1007/s00018-009-0020-8</pub-id><pub-id pub-id-type="pmid">19333550</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minogue</surname><given-names>AM</given-names></name><name><surname>Stubbs</surname><given-names>AK</given-names></name><name><surname>Frigerio</surname><given-names>CS</given-names></name><name><surname>Boland</surname><given-names>B</given-names></name><name><surname>Fadeeva</surname><given-names>JV</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><etal/></person-group><article-title>gamma-secretase processing of APLP1 leads to the production of a p3-like peptide that does not aggregate and is not toxic to neurons</article-title><source>Brain Res</source><year>2009</year><volume>1262</volume><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2009.01.008</pub-id><pub-id pub-id-type="pmid">19401174</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumkotter</surname><given-names>F</given-names></name><name><surname>Wagner</surname><given-names>K</given-names></name><name><surname>Eggert</surname><given-names>S</given-names></name><name><surname>Wild</surname><given-names>K</given-names></name><name><surname>Kins</surname><given-names>S</given-names></name></person-group><article-title>Structural aspects and physiological consequences of APP/APLP trans-dimerization</article-title><source>Exp Brain Res</source><year>2012</year><volume>217</volume><fpage>389</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s00221-011-2878-6</pub-id><pub-id pub-id-type="pmid">21952790</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggert</surname><given-names>S</given-names></name><name><surname>Paliga</surname><given-names>K</given-names></name><name><surname>Soba</surname><given-names>P</given-names></name><name><surname>Evin</surname><given-names>G</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Weidemann</surname><given-names>A</given-names></name><etal/></person-group><article-title>The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>18146</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1074/jbc.M311601200</pub-id><pub-id pub-id-type="pmid">14970212</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name><name><surname>Hung</surname><given-names>AY</given-names></name><name><surname>Vigo-Pelfrey</surname><given-names>C</given-names></name><name><surname>Mellon</surname><given-names>A</given-names></name><name><surname>Ostaszewski</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Amyloid beta-peptide is produced by cultured cells during normal metabolism</article-title><source>Nature</source><year>1992</year><volume>359</volume><fpage>322</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1038/359322a0</pub-id><pub-id pub-id-type="pmid">1383826</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagida</surname><given-names>K</given-names></name><name><surname>Okochi</surname><given-names>M</given-names></name><name><surname>Tagami</surname><given-names>S</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Kodama</surname><given-names>TS</given-names></name><name><surname>Nishitomi</surname><given-names>K</given-names></name><etal/></person-group><article-title>The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system</article-title><source>EMBO Mol Med</source><year>2009</year><volume>1</volume><fpage>223</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1002/emmm.200900026</pub-id><pub-id pub-id-type="pmid">20049724</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naruse</surname><given-names>S</given-names></name><name><surname>Thinakaran</surname><given-names>G</given-names></name><name><surname>Luo</surname><given-names>JJ</given-names></name><name><surname>Kusiak</surname><given-names>JW</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effects of PS1 deficiency on membrane protein trafficking in neurons</article-title><source>Neuron</source><year>1998</year><volume>21</volume><fpage>1213</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(00)80637-6</pub-id><pub-id pub-id-type="pmid">9856475</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Fadeeva</surname><given-names>JV</given-names></name><name><surname>LaVoie</surname><given-names>MJ</given-names></name><name><surname>Paliga</surname><given-names>K</given-names></name><name><surname>Eggert</surname><given-names>S</given-names></name><name><surname>Kimberly</surname><given-names>WT</given-names></name><etal/></person-group><article-title>gamma-Secretase cleavage and binding to FE65 regulate the nuclear translocation of the intracellular C-terminal domain (ICD) of the APP family of proteins</article-title><source>Biochemistry</source><year>2003</year><volume>42</volume><fpage>6664</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1021/bi027375c</pub-id><pub-id pub-id-type="pmid">12779321</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Sudhof</surname><given-names>TC</given-names></name></person-group><article-title>Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>10542</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310001200</pub-id><pub-id pub-id-type="pmid">14699153</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagami</surname><given-names>S</given-names></name><name><surname>Okochi</surname><given-names>M</given-names></name><name><surname>Yanagida</surname><given-names>K</given-names></name><name><surname>Kodama</surname><given-names>T</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Kuwano</surname><given-names>R</given-names></name><etal/></person-group><article-title>Relative ratio and level of amyloid-beta 42 surrogate in cerebrospinal fluid of familial Alzheimer disease patients with presenilin 1 mutations</article-title><source>Neurodegener Dis</source><year>2014</year><volume>13</volume><fpage>166</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1159/000355258</pub-id><pub-id pub-id-type="pmid">24192669</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Kimura T, Kawano K, Doi E, Kitazawa N, Shin K, Miyagawa T, et al. inventors; Cinnamide compound patent PCT Int. Appl. WO2005115990(A1). 2005.</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilsson-Rahmberg</surname><given-names>M</given-names></name><name><surname>Olovson</surname><given-names>SG</given-names></name><name><surname>Forshult</surname><given-names>E</given-names></name></person-group><article-title>Method for long-term cerebrospinal fluid collection in the conscious dog</article-title><source>J Invest Surg</source><year>1998</year><volume>11</volume><fpage>207</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.3109/08941939809098035</pub-id><pub-id pub-id-type="pmid">9743488</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtta</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Mirgorodskaya</surname><given-names>E</given-names></name><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Gobom</surname><given-names>J</given-names></name></person-group><article-title>Peptidome analysis of cerebrospinal fluid by LC-MALDI MS</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e42555</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0042555</pub-id><pub-id pub-id-type="pmid">22880031</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Holtta</surname><given-names>M</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Bjerke</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Westerlund</surname><given-names>A</given-names></name><etal/></person-group><article-title>Altered cerebrospinal fluid levels of amyloid beta and amyloid precursor-like protein 1 peptides in Down&#x02019;s syndrome</article-title><source>Neuromolecular Med</source><year>2014</year><volume>16</volume><fpage>510</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s12017-014-8302-1</pub-id><pub-id pub-id-type="pmid">24740518</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanngren</surname><given-names>J</given-names></name><name><surname>Ottervald</surname><given-names>J</given-names></name><name><surname>Parpal</surname><given-names>S</given-names></name><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Stromberg</surname><given-names>K</given-names></name><name><surname>Borgegard</surname><given-names>T</given-names></name><etal/></person-group><article-title>Second generation gamma-secretase modulators exhibit different modulation of Notch beta and Abeta production</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>32640</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.376541</pub-id><pub-id pub-id-type="pmid">22851182</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kukar</surname><given-names>TL</given-names></name><name><surname>Ladd</surname><given-names>TB</given-names></name><name><surname>Bann</surname><given-names>MA</given-names></name><name><surname>Fraering</surname><given-names>PC</given-names></name><name><surname>Narlawar</surname><given-names>R</given-names></name><name><surname>Maharvi</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Substrate-targeting gamma-secretase modulators</article-title><source>Nature</source><year>2008</year><volume>453</volume><fpage>925</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nature07055</pub-id><pub-id pub-id-type="pmid">18548070</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebke</surname><given-names>A</given-names></name><name><surname>Luebbers</surname><given-names>T</given-names></name><name><surname>Fukumori</surname><given-names>A</given-names></name><name><surname>Shirotani</surname><given-names>K</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Baumann</surname><given-names>K</given-names></name><etal/></person-group><article-title>Novel &#x003b3;-secretase enzyme modulators directly target presenilin protein</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><fpage>37181</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1074/jbc.C111.276972</pub-id><pub-id pub-id-type="pmid">21896486</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pozdnyakov</surname><given-names>N</given-names></name><name><surname>Murrey</surname><given-names>HE</given-names></name><name><surname>Crump</surname><given-names>CJ</given-names></name><name><surname>Pettersson</surname><given-names>M</given-names></name><name><surname>Ballard</surname><given-names>TE</given-names></name><name><surname>Am Ende</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Gamma-secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><fpage>9710</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.398602</pub-id><pub-id pub-id-type="pmid">23396974</pub-id></element-citation></ref></ref-list></back></article>